Navigation Links
Updated data on novel HPV vaccine confirms efficacy in large population

Updated data from a study on a promising new vaccine against a pre-cancerous cervical virus shows superior efficacy in preventing cervical pre-cancers and non-invasive cervical cancer, according to a study presented today during the American Association for Cancer Research's 4th Annual Frontiers in Cancer Prevention Research meeting in Baltimore.

Final results of the phase III study, originally published in early October, confirmed the vaccine's efficacy from available combined phase II and phase III data sets, incorporating an additional 7,000 patient records as compared to the interim results. The researchers concluded from these analyses that the administration of this vaccine, known as GARDASIL, is highly effective in preventing high-grade pre-cancerous illnesses and non-invasive cervical cancers.

Of the 8,487 women who received the vaccine, none were diagnosed with high-grade cervical pre-cancers (CIN 2/3+, cervical intraepithelial neoplasia) or non-invasive cervical cancers associated with human papillomavirus (HPV) types 16 and 18. Of the 8,460 women who did not receive the vaccine, 53 such cases were diagnosed.

In the larger population analysis, which included women who may have become infected with HPV during the vaccination period or who may have violated the protocol (e.g. by missing visits, etc.), the vaccine prevented 99 percent of HPV 16 or 18-related high-grade cervical pre-cancers (1 of 9,342 pts versus 81 of 9,400 in the placebo group) with an average follow up of 25 months.

The vaccine was generally well tolerated, and the most common adverse event reported in the trial was local discomfort at the injection site.

The study is part of an ongoing phase III program involving more than 25,000 people in 33 countries. For the FUTURE II study, a prospective, randomized, double-blind, placebo-controlled study, women aged 16 to 26 years were randomized to receive a three-dose regimen of either the vaccine
'"/>

Source:American Association for Cancer Research


Page: 1 2

Related biology news :

1. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
2. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
3. GeneNotes - A novel information management software for biologists
4. Endocannabinoids ?the brains cannabis ?demonstrate novel modes of action to stress
5. A novel virus for croup
6. Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses
7. A novel method to measure circadian cycles
8. UCSD discovery may provide novel method to generate medically useful proteins
9. Neurons generated in the adult brain learn to respond to novel stimuli
10. Federal grant funds research on novel HIV therapy
11. Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Updated data novel HPV vaccine confirms efficacy large population

(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Ill. (June 18, 2012) Seeking to solve some ... source facilities at national research laboratories in the United ... Canadian Light Source and the Advanced Photon Source (APS) ... Laboratory agreed in January 2012 to a Partner User ...
... , PHILADELPHIA Healthy humans harbor an enormous and ... within their intestines. These microbial partners provide beneficial aid ... the development of a healthy immune system. In a ... , David Artis, PhD, associate professor of Microbiology, and ...
... to the simple sponge to find clues about the evolution ... a mechanism that coordinates the expression of genes that lead ... of the animal world may not be so distant after ... network," are published in the Proceedings of the National ...
Cached Biology News:Advanced Photon Source and Canadian Light Source strengthen ties 2Brothers in arms: Commensal bacteria help fight viruses 2Clues to nervous system evolution found in nerve-less sponge 2
(Date:5/29/2015)... May 29, 2015 GeneWEAVE, ... organisms (MDROs), announced that initial feasibility data supporting ... detection and susceptibility testing from positive blood cultures ... May 31, 2015 in New Orleans, LA. The ... molecular diagnostics that can quickly detect bacteria and ...
(Date:5/29/2015)... 2015 The Academy of Model Aeronautics ... school graduates from across the nation. , The Academy ... qualified AMA Youth Members with scholarships to pursue technical ... Program has awarded nearly $900,000 to college-bound aero-modelers. The ... organizations and individuals, AMA member donations, a portion of ...
(Date:5/29/2015)... Asthma treatment could   see significant ... enter arena, says   GBI Research ... of the leading asthma brands, such as Advair (fluticasone ... global market for asthma treatment is set to witness ... New analysis from business intelligence provider GBI ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
Breaking Biology Technology:Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... of... -- CAMBRIDGE, Massachusetts, August 26, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... New York State Department of Health has licensed Genelex Corporation,s ... state. The issued Clinical Laboratory Permit is for DNA testing ... 50 percent of the most commonly prescribed medicines. Research shows ... the genetic coding for these enzymes, greatly increasing their risk ...
... CFO -- LONDON, August 26, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9New York State Licenses Personalized Prescribing DNA Tests 2Hikma - Half Year Results Interviews With CEO and CFO 2Hikma - Half Year Results Interviews With CEO and CFO 3Hikma - Half Year Results Interviews With CEO and CFO 4Hikma - Half Year Results Interviews With CEO and CFO 5